Compare Incyte Corporation (INCY) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Jabil Inc — how do they compare? Incyte Corporation trades at $112.97 (market cap $22.85B), while Jabil Inc trades at $300.75 (market cap $31.35B). The key difference: Jabil Inc is the larger of the two by market cap, and Jabil Inc pays a 0.11% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Jabil Inc for 23 Days on average.
| INCY | JBL | |
|---|---|---|
Market Cap | $22.85B | $31.35B |
Volume | 1,927,029 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $129.93 | $385.50 |
52-Week Low | $83.80 | $192.49 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $18.35B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
JBL trades at $301.76, up 0.76% today, with a bearish technical signal despite strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $29.80B in 2025 and a high ROE of 74.11%, though net margins are thin at 2.9%. AI infrastructure demand is driving optimistic fiscal 2027 guidance, with a consensus analyst price target of $434.75 implying significant upside.
The outlook is positive due to accelerating AI-led growth and strong analyst support, but risks include market volatility post-earnings and high valuation multiples. Investment appeal hinges on execution of projected 24% revenue growth, while current technical weakness may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
